Journal ArticleDOI
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B. Buse,Julio Rosenstock,Giorgio Sesti,Wolfgang E. Schmidt,Eduard Montanya,Jason Brett,Marcin Zychma,Lawrence Blonde +7 more
TLDR
Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated, suggesting that liragLutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations.About:
This article is published in The Lancet.The article was published on 2009-07-04. It has received 1414 citations till now. The article focuses on the topics: Glycemic efficacy & Exenatide.read more
Citations
More filters
Journal ArticleDOI
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +9 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies,Melanie J. Davies,David A. D'Alessio,Judith E. Fradkin,Walter N. Kernan,Chantal Mathieu,Geltrude Mingrone,Geltrude Mingrone,Peter Rossing,Peter Rossing,Apostolos Tsapas,Deborah J. Wexler,John B. Buse +12 more
TL;DR: A panel to update the prior position statements on the management of type 2 diabetes in adults includes additional focus on lifestyle management and diabetes self-management education and support and efforts targeting weight loss.
Journal ArticleDOI
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
TL;DR: The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.
Journal ArticleDOI
Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
TL;DR: The genetic, environmental, and immunological data underlying the prevention and intervention strategies to constrain T1D are explained, including the efficacy of antigen-specific and antigen-nonspecific immune interventions.
Journal ArticleDOI
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup,Stephan Rössner,Luc Van Gaal,Aila Rissanen,Leo Niskanen,Mazin Al Hakim,Jesper J. Madsen,MF Rasmussen,Michael E. J. Lean +8 more
TL;DR: Liraglutide treatment over 20 weeks is well tolerated, induces weight loss, improves certain obesity-related risk factors, and reduces prediabetes.
References
More filters
Journal ArticleDOI
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan,John B. Buse,Mayer B. Davidson,Ele Ferrannini,Rury R. Holman,Robert S. Sherwin,Bernard Zinman +6 more
TL;DR: This revision of the consensus algorithm for the medical management of type 2 diabetes focuses on the new classes of medications that now have more clinical data and experience and addresses safety issues surrounding the thiazolidinediones.
Book ChapterDOI
Ethical principles for medical research involving human subjects
TL;DR: This document describes the aims and responsibilities of the World Medical Association (WMA) and its members and provides a history of its activities and activities.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes
TL;DR: Exenatide was generally well tolerated and reduced HbA 1c with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin this article.
Journal Article
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes
TL;DR: Exenatide was generally well tolerated and reduced HbA(1c) with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin.
Journal ArticleDOI
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
TL;DR: Exenatide significantly reduced HbA(1c) in patients with type 2 diabetes failing maximally effective doses of a sulfonylurea as monotherapy and was associated with weight loss.